Connect Biopharma Holdings Ltd cotiza a 0.90 USD y tiene una capitalización bursátil de $57M. En los últimos 12 meses ha facturado $3M con un margen de flujo de caja libre del -80687.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Th…
| Periodo | 2026-03 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | $-0.27 | $-0.31 | $-0.23 | $-0.19 |
| Estimado | $-0.30 | $-0.23 | $-0.22 | $-0.26 |
| Sorpresa | +10.0% | -34.8% | -4.5% | +26.9% |
| Métrica | CNTB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -90740.6% | -38.6% | -90702.0% |
| Net Margin | -86687.5% | -33.6% | -86653.9% |
| FCF Margin | -80687.5% | -13.9% | -80673.6% |
| ROE | -132.2% | -40.4% | -91.8% |
| ROA | -98.9% | -32.0% | -66.9% |
| Current Ratio | 3.74 | 2.84 | +0.90 |
| Debt / Equity | — | 0.28 | — |